LFB Biomanufacturing
Caroline Cauderlier possesses extensive experience in quality control within the pharmaceutical and biotechnology sectors. Currently serving as Responsable laboratoire contrôle qualité at LFB Biomanufacturing since December 2011, Caroline oversees physico-chemical testing of raw materials for therapeutic biotechnology products. Prior to this role, Caroline worked as a Technicien de Laboratoire at the European Directorate for the Quality of Medicines and Health Care, ensuring analytical precision for pharmaceutical samples. Caroline's earlier experience includes a position as Technicienne de Laboratoire Contrôle Qualité at Eli Lilly and Company, where quality assurance for insulin products was a key responsibility. Caroline holds a Maîtrise de BIOCHIMIE in Organic Chemistry from Université de Montpellier II, a Licence de Biochimie in Organic Chemistry from Université Montpellier 2, and a DEUG in BioPhysicoChemistry and Inorganic Chemistry from Université Louis Pasteur.
LFB Biomanufacturing
LFB Biomanufacturing is an expert CDMO in the development and manufacture of recombinant proteins via cell culture, with specific know-how in the area of monoclonal antibodies (mAbs). LFB Biomanufacturing supplies a full range of bioproduction services, from the development of cell lines to the manufacturing clinical and commercial batches of active substances from biological products up to multiple pool of 2000L Cell Culture production capacities using Disposable Bioreactors Technology and exclusively Single-Use systems. The Alès site is regulary inspected by Customers as well as Health Agencies, including French-ANSM and US-FDA. LFB Biomanufacturing is subsidiary of the LFB Group.